CD Biosynsis provides professional Cysteine-Specific PEGylation services, offering a high-precision site-specific conjugation strategy for the development of therapeutic proteins, antibodies, and peptides. Cysteine-specific PEGylation is often preferred over random lysine modification because cysteine residues are relatively rare on protein surfaces, allowing for better control over the stoichiometry and location of the polyethylene glycol polymer. By targeting either natural free cysteines or genetically engineered cysteine residues through Thio-PEGylation, we produce homogeneous conjugates with predictable pharmacokinetics and preserved biological activity.
Our technical team utilizes a variety of sulfhydryl-reactive chemistries, including maleimide, haloacetyl, and vinyl sulfone derivatives, to achieve stable and efficient coupling. This site-specific approach is particularly advantageous for maintaining the potency of the protein, as the PEG chain can be positioned away from the active site or receptor-binding domains. Whether you are working on half-life extension for small proteins or the development of complex antibody-drug conjugates, our platform provides verified homogeneity and full structural characterization of the final PEGylated product.
Get a QuoteCysteine-specific PEGylation relies on the high nucleophilicity of the thiolate anion at physiological pH levels. Compared to the abundant amino groups of lysine residues, the sulfhydryl group of cysteine offers a unique chemical handle for site-selective modification. In proteins where free cysteines are not naturally available, our protein engineering team can perform cysteine scanning mutagenesis to introduce a single cysteine residue at an optimal surface-exposed position, ensuring that the subsequent PEGylation does not interfere with the protein native fold or function.
Our platform excels in managing the redox environment required for successful cysteine conjugation. We provide specialized protocols for the mild reduction of masked or disulfide-bonded cysteines using reagents like TCEP or DTT, followed by rapid conjugation to prevent protein aggregation or misfolding. By utilizing high-resolution analytical tools such as mass spectrometry and Ellman assays, we confirm the exact number of PEG chains attached and the site-specific fidelity of the conjugation, providing a well-defined molecular entity for therapeutic development.
Reaction Mechanism
The most common method, utilizing Michael addition of the thiol to the maleimide ring at pH 6.5 to 7.5 to form a stable thioether bond.
Selectivity
Excellent selectivity for thiols over amines, roughly 1000-fold within the specified physiological pH range.
Mechanism
Nucleophilic substitution where the thiolate displaces a halogen atom, resulting in an extremely stable thioether linkage.
Stability
Provides a bond that is resistant to the retro-Michael reactions sometimes observed with maleimide conjugates in serum.
Exchange Reaction
Utilizing PEG-ortho-pyridyl disulfide to form a reversible disulfide bond with the protein cysteine.
Applications
Ideal for applications requiring intracellular release of the protein or when the PEG shield must be removed under reducing conditions.
Our systematic pipeline ensures high-yield conjugation and comprehensive characterization of the site-specific product.
1. Structural Evaluation
2. Reduction and Activation
3. Purification
4. Analytical Characterization
Assessment of free thiol availability via Ellman assays. Computational modeling to identify optimal sites for cysteine engineering if a free thiol is not naturally present.
Controlled reduction of native disulfides or removal of cysteine capping. Optimization of pH and molar ratios of the cysteine-reactive PEG reagent.
Purity confirmation via gel electrophoresis and HPLC. Molecular weight verification by MALDI-TOF or ESI mass spectrometry. Site-specific confirmation by peptide mapping and bioactivity validation.
Unmatched Homogeneity
Achieve a highly uniform product with precise control over the PEG-to-protein ratio, essential for clinical consistency and regulatory approval.
Preserved Bioactivity
By selecting distal cysteine sites, we ensure that the PEG polymer provides a shield against proteolysis without blocking active pockets or receptor binding.
Expert Engineering
Full support for Thio-modification through the introduction of de novo cysteine residues at strategic surface locations via site-directed mutagenesis.
Regulatory-Ready Data
Comprehensive analytical documentation confirming site-specificity and purity, suitable for IND and NDA filings.
1. What if my protein does not have a free cysteine residue?
We can utilize cysteine scanning mutagenesis to introduce a cysteine residue at a surface-exposed site. Our modeling team ensures the site is chosen to maximize PEGylation efficiency while minimizing the impact on biological function.
2. Are maleimide-thiol bonds stable in vivo?
While generally stable, thioether bonds formed by maleimides can undergo retro-Michael reactions in the blood. If extreme stability is required, we offer haloacetyl or vinyl sulfone chemistries as superior alternatives for long-term stability.
3. How do you prevent multi-PEGylation if multiple thiols are present?
If multiple free thiols are present, we optimize the stoichiometry and reaction time carefully. Additionally, we use high-resolution chromatography to separate mono-PEGylated variants from poly-PEGylated species.
4. Does PEGylation affect the isoelectric point of the protein?
Unlike lysine-specific PEGylation which consumes a positive charge, cysteine-specific thioether formation does not alter the charge of the protein, typically resulting in no change to the pI.
5. How is the PEGylation efficiency measured?
We use Ellman assays before and after the reaction to measure the decrease in free thiol concentration. Final efficiency and stoichiometry are confirmed by HPLC and mass spectrometry.
6. Can you perform PEGylation on antibody fragments like ScFv or Fab?
Yes, cysteine-specific modification is a standard method for PEGylating antibody fragments to increase their molecular weight above the renal clearance threshold while maintaining antigen binding.
7. What molecular weights of PEG are available?
We offer a wide range of cysteine-reactive PEGs, from 5kDa up to 40kDa, in both linear and branched architectures to meet specific half-life requirements.
8. What is the typical turnaround time for a PEGylation project?
A standard project from design to the delivery of the purified conjugate typically takes 6 to 10 weeks, depending on the complexity of the protein and the required purification steps.
Would you like to discuss the feasibility of introducing a cysteine residue into your protein sequence for site-specific half-life extension?
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.